Perpetual Nyame

Perpetual Nyame

Auto-generated profile, based on publicly available information

Perpetual Nyame

Department of Microbiology, Faculty of Life Sciences, Kumamoto University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PNPerpetual Nyame
Perpetual Nyame
ATAkihiro Togami
Akihiro Togami
TYTomofumi Yoshida
Tomofumi Yoshida
TMTakuya Masunaga
Takuya Masunaga
MBMst Monira Begum
Mst Monira Begum
KMKazuaki Monde
Kazuaki Monde
The introduction of combined antiretroviral therapy (cART) has greatly improved the quality of life of human immunodeficiency virus type 1 (HIV-1)-infected individuals. Nonetheless, the ever-present desire to seek out a full remedy for HIV-1 infections makes the discovery of novel antiviral medication compelling. Owing to this, a new late-stage inhibitor, Lenacapavir/Sunlenca, an HIV multi-phase suppressor, was clinically authorized in 2022. Besides unveiling cutting-edge antivirals inhibiting late-stage proteins or processes, newer therapeutics targeting host restriction factors hold promise for the curative care of HIV-1 infections. Notwithstanding, bone marrow stromal antigen 2 (BST2)/Tetherin/CD317/HM1.24, which entraps progeny virions is an appealing HIV-1 therapeutic candidate. In this study, a novel drug screening system was established, using the Jurkat/Vpr-HiBiT T cells, to identify drugs that could obstruct HIV-1 release; the candidate compounds were selected from the Ono Pharmaceutical compound library. Jurkat T cells expressing Vpr-HiBiT were infected with NL4-3, and the amount of virus release was quantified indirectly by the amount of Vpr-HiBiT incorporated into the progeny virions. Subsequently, the candidate compounds that suppressed viral release were used to synthesize the heterocyclic compound, HT-7, which reduces HIV-1 release with less cellular toxicity. Notably, HT-7 increased cell surface BST2 coupled with HIV-1 release reduction in Jurkat cells but not Jurkat/KO-BST2 cells. Seemingly, HT-7 impeded simian immunodeficiency virus (SIV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) release. Concisely, these results suggest that the reduction in viral release, following HT-7 treatment, resulted from the modulation of cell surface expression of BST2 by HT-7.

3 September 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
WAWright Andrews Ofotsu Amesimeku
Wright Andrews Ofotsu Amesimeku
YNYoshihiro Nakata
Yoshihiro Nakata
NMNami Monde
Nami Monde
HTHiromi Terasawa
Hiromi Terasawa
HOHirorka Ode
Hirorka Ode
KMKazuaki Monde
Kazuaki Monde
Lenacapavir (LEN), a potent capsid inhibitor, suppresses reverse transcription and nuclear import by disrupting capsid core formation in HIV type 1 (HIV-1). However, its effects on late-stage viral assembly remain unclear. Although p24 ELISA suggested that LEN substantially inhibited HIV-1, both RT-dPCR and Vpr-HiBiT assays indicated that suppression of viral release required relatively high LEN concentrations. This discrepancy was attributed to LEN-induced reduction in p24 solubility, leading to an overestimation of its inhibitory effect on viral release. In addition, excessive intracellular Gag processing by the viral protease was observed in the presence of LEN, which contributed to impaired viral release. Furthermore, LEN induced numerous abnormal, discrete clusters of Gag at the plasma membrane. Using mass photometry, which was applied to analyze HIV-1 particle sizes, and transmission electron microscopy, we identified heterogeneous LEN-induced viral-like particles (LENiVLPs; diameter >200 nm) containing both Gag and Env proteins. Although LENiVLPs retained membrane fusion capability, they were noninfectious owing to postentry defects that prevented viral replication. Thus, LEN binds to the precursor Gag and promotes aberrant particle formation, offering insights that could guide the development of next-generation LEN-based therapeutics targeting the late stages of the viral life cycle.

15 March 2026 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
PNPerpetual Nyame
Perpetual Nyame
OOOlayinka S. Okoh
Olayinka S. Okoh
AYakua k yalley
akua k yalley
NNNicholas Israel Nii-Trebi
Nicholas Israel Nii-Trebi